TriangleNCT01947140 · OUTCOME
Progression Free Survival (PFS) of Subjects in Phase 2
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- Up to 3 years
What was measured
PFS was defined as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the PFS is one way to see how well a new treatment works.
Groups in this outcome
Phase II
Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 intravenously once weekly on days 1 and 15 on a 28-day cycle.
| Group | Source count |
|---|---|
| Phase II | 18 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase II | 3.1 | Not reported | 2.5 | 4.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.5
- upper Limit
- 4.8
- value
- 3.1
- denoms
- counts
- group Id
- OG000
- value
- 18
- units
- Participants
- description
- PFS was defined as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the PFS is one way to see how well a new treatment works.
- dispersion Type
- Inter-Quartile Range
- groups
- description
- Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 intravenously once weekly on days 1 and 15 on a 28-day cycle.
- id
- OG000
- title
- Phase II
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Up to 3 years
- title
- Progression Free Survival (PFS) of Subjects in Phase 2
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0
Preserved source evidence · Not medical advice